Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S & P 500’s performance over the past three years. The study results released by Eli Lilly on Wednesday highlight the … Read more
Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC WeightWatchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial position of the company is solid and its new clinical business related to the threat of GLP-1 weight loss drugs is growing faster than expected. … Read more
There may be a stronger case to invest in single stocks over exchange-traded funds in the weight loss space. Amplify ETFs and Roundhill Investments each filed a prospectus last week to launch funds focused on weight loss companies, a move that Strategas ETF and technical strategist Todd Sohn believes hinges on the performance of two … Read more
The popular weight-loss drug Wegovy, which has helped millions of Americans shed pounds, can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, federal regulators said Friday. The U.S. Food and Drug Administration approved a label change requested by … Read more
Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a new dilemma: What happens if they stop taking them? Many worry, rightly, that they’ll regain weight and revert to old habits. In clinical trials, patients who paused the drugs put back on most of the … Read more
With obesity rates rising in Canada and globally, new research suggests there is a higher risk of stillbirth in mothers with obesity. Experts say early delivery could help minimize those risks. The study published in the Canadian Medical Association Journal (CMAJ) Monday found that maternal obesity on its own and along with other risk factors, … Read more
More than one billion people worldwide are grappling with obesity, with children in particular experiencing alarming increases in numbers, a new study shows. A global analysis published in the Lancet on Thursday found that obesity rates in children and adolescents across the world surged fourfold from 1990 to 2022. During this period, obesity rates more … Read more
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan Mcdermid | Reuters For all of the promise associated with new weight loss drugs such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound in treating obesity, there’s a very big risk printed right on … Read more
Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag â typically between $1,000 to $1,500 a month â consumers are clamoring for drugs like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. This class of drugs, historically used to … Read more
Evercore ISI’s Julian Emanuel thinks Nvidia’s monster rally is fueling a fear of missing out in the market. He finds clients, including many who traded through the dot-com boom and subsequent collapse, are more worried about being underinvested than overexposed right now. “That’s the first time that’s happened since 2021 for us,” the firm’s senior … Read more
